According to published reports, life science startup, Sphere Fluidics, is hiring fast after closing a POUND1.6m funding round - which included a POUND133k investment by a syndicate of London Business Angels group.

The company is ramping up to accelerate commercialisation of the technology. Sphere is commercialising a single cell analysis technology which it says can accelerate new bio-pharmaceutical discovery, generate stem cell therapies and enable novel studies on single cell diseases such as cancer.

The picodroplet technology, using a microfluidic chip, can perform up to eight million single cell tests per day and has already been used by a number of blue chip clients.

Anthony Clarke, London Business Angels CEO, described the technology as groundbreaking and felt it had the potential for "explosive growth."

The new funding round will enable Sphere Fluidics to expand its management resources, relocate to a new facility and accelerate sales growth. It has started advertising for a director of R & D, a commercial director and principal scientists.